regulatory associated protein of MTOR complex 1Genealiases: KOG1 · Mip1
Q-omics provides the consensus-scored RPTOR profile across patient tissues and cancer cell-line models. RPTOR expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPTOR is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, RPTOR RNA expression shows 20,378 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where RPTOR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPTOR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPTOR survival associations across molecular data types. RPTOR RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPTOR RNA expression–survival associations across cancer types. High RPTOR expression shows unfavorable associations in ACC, BLCA, LIHC, MESO and LGG, but favorable associations in BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPTOR RNA expression.
This table summarizes RPTOR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPTOR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPTOR shows lower tumor expression in THCA and BLCA and higher tumor expression in HNSC, KIRP, LIHC and KIRC. The HNSC box plot shows higher RPTOR RNA expression in tumor versus normal tissue (log2 FC = +0.857, t-test p < 0.001).
This table shows molecular features associated with RPTOR in patient tissues and cancer cell lines. In patient samples, RPTOR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPTOR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
